Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics - 1 Jun 2015

Komaki Ritsuko, Allen Pamela K, Wei Xiong, Blumenschein George R, Tang Ximing, Lee J Jack, Welsh James W, Wistuba Ignacio I, Liu Diane D, Hong Waun Ki

Abstract excerpt

PURPOSE: To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent chemoradiotherapy for previously untreated, locally advanced, inoperable non-small cell lung cancer would improve survival and disease control without increasing toxicity. METHODS AND MATERIALS: Forty-eight patients with previously untreated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Drug Administration Schedule

Share to Erlotinib Hydrochloride

Share to Feasibility Studies

Share to Paclitaxel

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 25968826
DOI: 10.1016/j.ijrobp.2015.02.005
PMCID: PMC4432249

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.PMID 25968826Read ↗

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.Semantic proximity Read ↗

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.Semantic proximity Read ↗

Concurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional AnalysisSemantic proximity Read ↗

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.Semantic proximity Read ↗

Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.Semantic proximity Read ↗

Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.Semantic proximity Read ↗

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.Semantic proximity Read ↗

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.Semantic proximity Read ↗

Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.